メインコンテンツに移動

Deals of the month - Glaxosmithkline

Rare issuer GlaxoSmithKline has made a storming return to the bond market with a $9 billion financing across four tranches featuring maturities ranging from two to 30 years. The deal is the largest pharmaceutical trade ever and the largest dollar-denominated corporate bond since 2001. It was led by Citigroup, JPMorgan and Lehman Brothers.

While GSK had been absent from the market since 2004

コンテンツを印刷またはコピーできるのは、有料の購読契約を結んでいるユーザー、または法人購読契約の一員であるユーザーのみです。

これらのオプションやその他の購読特典を利用するには、info@risk.net にお問い合わせいただくか、こちらの購読オプションをご覧ください: http://subscriptions.risk.net/subscribe

現在、このコンテンツをコピーすることはできません。詳しくはinfo@risk.netまでお問い合わせください。

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

ログイン
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here